Relay’s Board of Directors includes some of the industry’s most established leaders. Our Board of Directors shares our vision to bring objective data-driven analysis to drug development.
Larry Miller, M.D.
Dr. Miller is a Partner and Founder of Mediphase Venture Partners. He has invested in more than 25 private companies in life sciences/health care.
Prior to founding Mediphase Venture Partners, Dr. Miller was Senior Vice President, Hambrecht & Quist Capital Management in Boston from 1997-1999, where he was responsible for evaluating all private equity investments. Before joining H&Q, he was Executive Vice President and Director, Internal Operations at Avicenna Systems Corp from 1996 to 1997. Avicenna was acquired by Synetic, Inc. (now WebMD) in 1996.
From 1990 to 1996, Dr. Miller was Vice President at HPR, Inc. as the company underwent dramatic growth and a successful IPO in 1995. HPR was acquired by HBOC in 1997. Dr. Miller served as a Senior Scientist at the Health Data Institute, Inc. from 1985 to 1987. He has consulted extensively for major pharmaceutical companies, including Pfizer, Roche, Upjohn and Boehringer Ingelheim.
Dr. Miller is trained as a physician and pharmacologist and was a faculty member in the Department of Pharmacology and Experimental Therapeutics at Tufts University School of Medicine in Boston. He has published more than 100 scientific papers, and received numerous awards in this field, including national awards from both major professional societies in clinical pharmacology. He is currently Adjunct Associate Professor of Pharmacology at Tufts and Instructor in Medicine at Harvard Medical School. Dr. Miller was educated at Harvard College, Cambridge University and Harvard Medical School, and completed his clinical training at the Massachusetts General Hospital in Boston. He is Board certified in Internal Medicine, Pulmonary Disease and Clinical Pharmacology.
David Greenwald, Ph.D – Co-founder & Managing Director
Dr. Greenwald is a cofounder of Relay Technology Management, Inc. and currently serves as Managing Director. Dr. Greenwald was an Associate Investigator at the Naval Medical Research Centerin Silver Spring, MD. Dr. Greenwald worked with the Food and Drug Administration (FDA) on 510(k) applications for diagnostic devices for dengue fever. Dr. Greenwald was a Howard Hughes Medical Institute (HHMI) research fellow while earning a B.S. in Cellular Biology and Molecular Genetics from the University of Maryland, College Park. Dr. Greenwald was awarded an NIH Ruth L. Kirschstein National Research Service Award (NRSA) towards his Ph.D. research dissertation on gene therapy for Retinitis Pigmentosa. Dr. Greenwald is an active Licensing Executive Society member, and serves on the Board of Directors for Piers Park Sailing Center in Boston, MA. Dr. Greenwald focuses on infectious diseases, cancer and genetics and enjoys sailing in Boston harbor. Dr. Greenwald publishes his perspectives on the entrepreneurism and the innovation economy on his personal blog
Brigham Hyde, Ph.D., Co-founder & Managing Director
Dr. Hyde is a cofounder of Relay Technology Management, Inc. and currently serves as Managing Director. Dr. Hyde was most recently an equity research analyst at Cowen and Company, as a member of the Healthcare Equity Research team with a focus on life science tools, genetic technologies, diagnostics, and the broader Medtech industry. Dr. Hyde is an Adjunct Professor and Lecturer at Tufts University Sackler School of Biomedical Science in the Department of Pharamcology. He has experience in pre-clinical drug development from CRO Wolfe Laboratories Inc. and has conducted research and published several articles in pharmacology and mitochondrial biology in the context of anemia, myelodysplastic syndromes, and type II diabetes. Dr. Hyde received his B.S. in Chemistry and a minor in Business Management from Northeastern University and a Ph.D.in Pharmacology and Experimental Therapeutics from Tufts University Sackler School of Biomedical Science. Dr. Hyde also publishes his perspectives on the emerging field of personalized medicine and genetic technology on his personal blog www.basepairstobedside.
Peter Collins, Ph.D. – Nature Publishing Group
Peter Collins has been a member of the Board of Nature Publishing Group since 2004 and is currently leading the creation of a Business Intelligence Unit focusing on serving the needs of corporate executives and scientists. Peter’s remit includes products and services focusing on biotechnology, pharmaceuticals, and translational research. Peter has publishing responsibility for Nature Medicine, Nature Biotechnology, Nature Reviews Drug Discovery, and Nature Chemical Biology. Peter and his team are also responsible for the development of products and partnerships that reside at the interface of science and business – such as SciBX with BioCentury and the nature.com open innovation pavilion with Innocentive. Peter is also responsible for Nature Conferences.
After joining the company from Elsevier in 2000 as the launch editor of Nature Reviews Neuroscience, Peter has held various publishing positions and at various times has been responsible for Nature, the Nature research titles, the Nature Reviews titles and sponsorship, display and classified advertising. Peter studied at London University (BSc in applied biology, PhD in neuroscience) and Cambridge University (6 years post-doctoral research).
